hapabapa
Share of Halozyme Therapeutics (HALO) slipped on Wednesday after Morgan Stanley downgraded the developer of Enhanze drug delivery technology, citing valuation concerns following its recent Q3 2026 results.
Analyst Sean Laaman downgraded HALO to Equal Weight from Overweight but raised